Ultromics

Stop by the @American_Heart AI Torch, powered by Dandelion, booth in the Innovation Pavilion at #AHA2026 to explore their independent assessment of Ultromics’ EchoGo® Heart Failure and its potential impact on patients and health systems. Stop by to explore the full impact report, or read it here: hubs.la/Q04DHR3D0 #ScientificSessions2026 #HFpEF #ClinicalAI

Earlier today at #AHA2026, @AshleyAkerman shared findings from the America Heart Association’s AI Impact report, highlighting EchoGo® Heart Failure’s potential to support identification of HFpEF an average of 263 days earlier than standard clinical practice. Explore the findings and what they could mean for your patients and health system in the full impact report: hubs.la/Q04DGXmd0 #AmericanHeart #ScientificSessions2026 #HFpEF #ClinicalAI

Behind the scenes today at #AHA2026 as we sit down with Dr. Vishal Gupta from Beacon Health Kalamazoo, Ross Upton, and other members of our team to hear their perspectives on bringing EchoGo® into clinical practice—from implementation to real-world experiences. Can’t wait to share! #ScienfiticSessions2026 #HFpEF #Amyloid #ClinicalAI

See you at #AHA2026! Members of our commercial team will be on site and look forward to connecting. Stop by booth #745 to learn how Ultromics’ advanced AI flags HFpEF and screens for cardiac amyloidosis from a single apical four-chamber view. #AHA #ScientificSessions2026 #Echocardiography #CardiacAmyloidosis #HFpEF

Not every mask comes off after Halloween. For patients with HFpEF or cardiac amyloidosis, overlapping symptoms and conditions can obscure the underlying disease. EchoGo® Heart Failure and EchoGo® Amyloidosis bring AI insights into routine echocardiography, helping clinicians identify patients who may benefit from further evaluation. Looking beyond the mask can help inform the next step in care. #HFpEF #CardiacAmyloidosis #HeartFailure #AIinHealthcare

Complex cardiac diseases don’t always present clearly. HFpEF and cardiac amyloidosis often present with nonspecific symptoms, comorbidities, and subtle cardiac findings—factors that can complicate recognition in standard clinical practice. Ultromics' clinically validated AI is applied to routine echocardiography to help clinicians identify HFpEF and screen for cardiac amyloidosis. Learn more at hubs.la/Q04CvGHY0 #HFpEF #CardiacAmyloidosis #HeartFailure #DigitalHealth #AIinHealthcare

This #WorldAmyloidosisDay, we’re highlighting the importance of recognizing cardiac amyloidosis—and the people whose lives are affected by it. At Ultromics, we’re working to bring AI insights into routine echocardiography to support earlier consideration of cardiac amyloidosis and inform further evaluation. Because behind every opportunity for earlier recognition is a patient waiting for answers. #WorldAmyloidosisDay #AmyloidosisAwareness #CardiacAmyloidosis

In addition to the information available on our website, our team is always happy to connect and discuss how Ultromics’ AI can support your clinical workflow. Visit hubs.la/Q04C2ZxB0 to connect with an EchoGo® expert and learn more. #ClinicalAI #HFpEF #ATTRCM #Echocardiography

Ultromics is headed to Chicago for #AHA2026! We're looking forward to connecting with attendees and sharing how our clinically validated AI, EchoGo® Heart Failure and EchoGo® Amyloidosis, integrates into existing echocardiography workflows to help clinicians identify HFpEF and screen for cardiac amyloidosis. #AHA26 #HFpEF #Amyloid #ATTRCM #ClinicalAI

What does bringing AI into clinical practice look like? Explore real-world evaluations and hear from clinicians using EchoGo® in practice—from implementation experiences to perspectives on how its insights help inform further evaluation and patient management. Explore here: hubs.la/Q04BrjRt0 #HFpEF #CardiacAmyloidosis #ATTRCM #ClinicalAI

What context does the AFib live in? During our HRX Live roundtable, panelists explored the importance of looking beyond the arrhythmia to understand potential underlying conditions such as cardiac amyloidosis. That broader clinical picture matters when considering the next steps in a patient’s care. Watch the full roundtable on YouTube: hubs.la/Q04BkBw50 #AFib #CardiacAmyloidosis #Electrophysiology #HRX2026

🚨Now available on YouTube- Hidden in Plain Sight: Earlier Detection of HFpEF and Cardiac Amyloidosis to Improve AF Ablation and LAAC Outcomes Hear from Ultromics Chief Commercial Officer @rogerrowens and leading experts in electrophysiology as they discuss earlier recognition, implications for patient management, and what it takes to integrate AI into clinical workflows. Watch the full roundtable: hubs.la/Q04B4kJz0 #HRX2026 #AFib #HFpEF #CardiacAmyloidosis

Heading to #HFSA2026? Join us for two ePoster presentations exploring EchoGo®’s role in HFpEF and cardiac amyloidosis detection. Then stop by booth #811 to meet the team and learn more!

See you at #HFSA2026! Members of our commercial team will be on site and look forward to connecting. Stop by booth #811 to learn how EchoGo® supports detection of HFpEF and Cardiac Amyloidosis within routine echocardiography. #HFSA #HFpEF #ATTRCM #Amyloid #ClinicalAI

Earlier identification matters when it helps inform the path forward. Hear from Dr. Faizi Jamal at City of Hope and other clinicians about how they’re using EchoGo® in practice and what it means for their health systems: ultromics.com #CardiacAI #Echocardiography #HFpEF #CardiacAmyloidosis #ATTRCM

A recent @MPOmagazine article highlights independent findings from the American Heart Association AI Assessment Lab, which found EchoGo® Heart Failure could have identified HFpEF an average of 263 days earlier than standard care among patients who otherwise experienced delayed diagnosis. These findings help bridge the gap between AI’s potential and its practical value, providing clinicians and health systems with evidence to assess how EchoGo could support earlier consideration of HFpEF alongside physician judgment. Read the full article: mpo-mag.com/breaking-news/re… #AmericanHeartAssociation #HFpEF #Echocardiography #ClinicalAI

Today is World Heart Day ❤️ Cardiovascular disease accounts for nearly one in three deaths worldwide. Behind that number are people whose symptoms may be overlooked and whose heart conditions may go unrecognized. At Ultromics, we’re bringing AI insights into routine echocardiography to help clinicians flag conditions like HFpEF and cardiac amyloidosis sooner—and move patients toward appropriate care pathways earlier. Because every patient deserves the chance to get the care they need. #WorldHeartDay #HeartHealth #Cardiology

Last week at HRX, our roundtable explored how earlier identification of HFpEF and cardiac amyloidosis could inform care for patients undergoing AF ablation and LAAC—and how EchoGo® may support earlier consideration of these conditions through routine echocardiography. Thank you to everyone who shared their perspectives and made it such a thoughtful conversation. We’re also grateful to @experienceHRX for bringing us together for a great meeting! Panelists: Michael Raccuglia JR., @rogerrowens, Robert Kowal, @TinaBaykaner45, @NazemAkoum, @TJaredBunch

Ultromics CCO @rogerrowens and Northeast Regional Sales Director Kim Kenyon are at NYU Langone Health today for Advances in the Diagnosis and Treatment of Amyloidosis in 2026. We’re excited to join clinicians and researchers discussing advances in imaging, diagnosis, and treatment. Stop by our booth to learn how FDA-cleared EchoGo® Amyloidosis can support earlier consideration of cardiac amyloidosis—and what that could mean for your health system. #CardiacAmyloidosis #Echocardiography #CardiacAI